Rice Technologies for Cervical Cancer Screening and Diagnosis
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 25-49 lat
- •Dodatni wynik badania przesiewowego raka szyjki macicy (nieprawidłowe wyniki cytologii, pozytywny test VIA lub pozytywny test HPV)
- •Nienaruszona szyjka macicy
- •Nie jest w ciąży i ma ujemny test ciążowy (w ciągu 14 dni przed włączeniem do badania)
- •Nie karmi piersią
- •Chęć i zdolność do wyrażenia świadomej zgody
✗ Disqualifies
- •Wiek poniżej 25 lat lub powyżej 49 lat
- •Całkowite usunięcie macicy z szyjką macicy
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 25 Years
- Maximum age
- 49 Years
- Last updated (source)
- August 10, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (4)
M D Anderson Cancer Center
Houston, United States
José Macamo General Hospital and Health Center
Maputo, Mozambique
Maputo Central Hospital
Maputo, Mozambique
Mavalane Hospital and Health Center
Maputo, Mozambique
Trial contact
Mila Salcedo, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.